NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









GRIP Molecular Technologies

GRIP Molecular Technologies

Private
Saint Paul, MinnesotaHealthcare & Life Scienceshttps://gripmolecular.com/

Last Round

Convertible Debt

May 30, 2023

Total Funding Raised

$8.81M

Company Overview

GRIP Molecular Technologies is a biotechnology company that develops CRISPR-based diagnostic platforms and electronic biosensors for rapid, point-of-need infectious disease testing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Sensors, Health IoT, Precision Medicine

Business Model

B2C

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

molecular diagnosticspoint-of-need testingCRISPR diagnosticselectronic biosensorsat-home testingPOC diagnosticspoint-of-caregraphene biosensorssmartphone diagnosticsdigital healthmedical devicestelehealth integrationrapid testingconsumer healthlab-on-a-chip

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GRIP Molecular Technologies Comparables

Compare GRIP Molecular Technologies with similar companies based on industry and business-model similarity.

GRIP Molecular Technologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sapphiros
83%
Nanopath
80%
VedaBio
79%

GRIP Molecular Technologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtMay 30, 2023
GrantJan 31, 2020

Key People

Founding team and executive leadership

Edward Gillen

Chief Executive Officer, Board Director

Executive Team

GRIP Molecular Technologies Investors

Notable investors and investment history

GRIP Molecular Technologies investors
InvestorRounds
Launch MinnesotaGrant
EvoNexusAccelerator
Minnesota Department of Employment and Economic DevelopmentGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 30, 2023

    $9M raised in convertible debt financing.

  • Jan 31, 2020

    Received grant funding from Launch Minnesota and DEED.

GRIP Molecular Technologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GRIP Molecular Technologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GRIP Molecular Technologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersSaint Paul, Minnesota
Employee Range13
Year Founded2019
Last FundingMay 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.